Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% above its 5-year average of -0.14, near the high end of its 5-year range (-1.08–0.02).
As of the fiscal period ended Tuesday, March 31, 2026. 100.00% above its 12-month average of -0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2026 (2026-03-31): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
-0.02
DEBT TO EQUITY RATIO AVG 3Y
-0.22
DEBT TO EQUITY RATIO AVG 5Y
-0.14
DEBT TO EQUITY RATIO AVG 10Y
0.00
DEBT TO EQUITY RATIO AVG 15Y
0.00
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
OKYO Pharma Limited
Market Cap
$56.98M
Debt to Equity Ratio
0.00
TTM Avg
-0.02
3Y Avg
-0.22
5Y Avg
-0.14
Market Cap
$57.72M
Debt to Equity Ratio
N/A
TTM Avg
1.49
3Y Avg
1.10
5Y Avg
0.74
Market Cap
$57.98M
Debt to Equity Ratio
0.00
TTM Avg
0.41
3Y Avg
0.41
5Y Avg
0.41
Market Cap
$58.79M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$59.00M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$54.50M
Debt to Equity Ratio
0.30
TTM Avg
0.30
3Y Avg
0.29
5Y Avg
0.25
Market Cap
$59.71M
Debt to Equity Ratio
N/A
TTM Avg
0.10
3Y Avg
0.06
5Y Avg
0.05
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.98M | 0.00 | -0.02 | -0.22 | -0.14 |
| Talphera, Inc. (TLPH)vs › | $57.09M | 0.00 | 0.60 | 0.42 | 0.42 |
| PDS Biotechnology Corporation (PDSB)vs › | $57.72M | N/A | 1.49 | 1.10 | 0.74 |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | 0.00 | 0.41 | 0.41 | 0.41 |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | N/A | 0.00 | 0.00 | 0.00 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.00M | 0.02 | 0.01 | 0.01 | 0.00 |
| Adicet Bio, Inc. (ACET)vs › | $59.17M | 0.11 | 0.09 | 0.09 | 0.11 |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $54.50M | 0.30 | 0.30 | 0.29 | 0.25 |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.71M | N/A | 0.10 | 0.06 | 0.05 |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.03M | 0.09 | 0.33 | 0.30 | 0.26 |
Debt/Equity
0.00
Current Ratio
2.43
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | 0.00 |
| 2025-09-30 | -0.05 |
| 2025-03-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-09-30 | -0.40 |
| 2023-03-31 | -1.08 |
| 2022-10-01 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-09-30 | 0.02 |
| 2021-03-31 | 0.02 |
| 2020-09-30 | 0.00 |
| 2020-03-31 | -0.23 |
| 2019-09-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-09-30 | 0.00 |
| 2013-03-31 | 0.00 |
| 2012-09-30 | 0.00 |
| 2012-03-31 | 0.00 |
| 2011-03-31 | 0.00 |
| 2010-09-30 | 0.00 |
| 2010-03-31 | 0.00 |
